Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

Genital Herpes Simplex Type 2 Clinical Trial

Official title:
A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection

Status Completed

Clinical Trial Summary

This study is a follow-up study from Study GEN-003-002 to evaluate long-term efficacy and immunogenicity of GEN-003 in subjects with genital HSV-2 infection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02910284
Study type	Observational
Source	Genocea Biosciences, Inc.
Contact
Status	Completed
Phase	N/A
Start date	September 16, 2016
Completion date	July 14, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02515175` - Evaluating New Formulation of Therapeutic HSV-2 Vaccine	Phase 2
Completed	`NCT02114060` - Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine	Phase 2
Completed	`NCT01667341` - Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine	Phase 1/Phase 2
Completed	`NCT02300142` - Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study	Phase 2
Recruiting	`NCT05432583` - A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions	Phase 1
Completed	`NCT02030301` - Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults	Phase 1/Phase 2